- Case Report
- Open Access
Bullous lesions as a manifestation of systemic lupus erythematosus in two Mexican teenagers
Pediatric Rheumatologyvolume 8, Article number: 19 (2010)
Rarely, systemic lupus erythematosus (SLE) presents with bullous lesions due to severe edema and hydropic degeneration of the basal layer, or as a subepidermal blistering disease. Here, we describe two Mexican teenagers, one with SLE with blisters and another with bullous SLE. We also discuss the mechanisms and clinical implications of lesion formation in patients with SLE and bullae.
Bullous lesions can occur in systemic lupus erythematosus (SLE) as a subepidermal blistering disease  or when severe edema and hydropic degeneration occur in the basal layer. The latter condition is considered a lupus erythematosus (LE)-specific lesion . The former condition is a rare disorder characterized by tense fluid-filled vesicles and bulla, with an erythematous or urticarial background. This condition is very rare in children, with only eleven cases reported to date [3–13] (Table 1). Here, we describe two females, aged 13 and 16 years, who presented with bullous lesions during the course of SLE.
Report of cases
A 13-year-old female presented with a macular and vesicular eruption of 3 days duration. On examination, several 1 mm to 2 mm clear or hemorrhagic tense vesicles over erythematous macules were identified in the left supracilliary region and on the neck (Figure 1). Several 10 mm to 20 mm erythematous macules were also present on the patient's trunk. Both the vesicles and the macules were pruriginous.
The patient had been diagnosed with SLE and lupus nephritis 2 months prior to the onset of the dermatosis, based on hemolytic anemia, lymphopenia, hypocomplementemia [C4 8 mg/dL (15-45), C3 116 mg/dL (83-177)], proteinuria (2.3 g/day), and positive antinuclear antibodies (1:640, diffuse pattern). She also had positive anti-dsDNA antibodies, positive anti-Ro antibodies, positive low titer IgM (26 MPL) and IgG (21GPL) anticardiolipin antibodies. She was prescribed oral prednisone and received three methylprednisolone boluses. The current dermatosis coincided with a new episode of hemolytic anemia and resolved with slight depigmentation within 10 days, after a fourth methylprednisolone pulse.
Histopathological study of a skin biopsy revealed a subepidermal blister with marked neutrophilic dermal infiltration (Figure 2) and a slight perivascular neutrophilic infiltrate. Direct immunofluorescence showed strong granular basement membrane zone IgG, IgA, C1q, and C3 deposition, and moderate granular vessel IgA and C1q deposits.
The patient did not experience another bullous eruption in the 3 years following that episode. Her SLE has predominantly been characterized by nephritis and hematologic disease, which have gradually resolved with cyclophosphamide, methylprednisolone boluses, and oral prednisone. During her most recent follow-up exam, cytotoxic treatment was suspended, oral prednisone was being tapered and hydroxychloroquine treatment had commenced.
A 16-year-old female presented with a purpuric and bullous eruption of 7 days duration. On examination, several 3 cm to 6 cm nummular purpuric plaques were disseminated on her trunk and extremities. The surface of each plaque contained a clear-fluid blister (Figure 3).
The patient had been diagnosed with SLE and secondary antiphospholipid syndrome (APS) 1 year prior to the onset of the dermatosis, based on hemolytic autoimmune anemia, lymphopenia, thrombocytopenia, proteinuria, serositis, cutaneous vasculitis, positive antinuclear antibodies, positive antiphospholipid antibodies, and a thrombus on the inferior cava vein. During the year prior to the onset of the bullous dermatosis, the patient had experienced several disease flares associated with persistent lymphopenia, with the main target organs being the central nervous system (vasculitis), kidney and liver. She was treated with methylprednisolone and cyclophosphamide boluses, as well as warfarin for APS, topiramate for seizures, and captopril for high blood pressure. During this period, the patient also developed warfarin skin necrosis and experienced three different septic events (due to E. faecium, Candida sp and Aspergillus) that required aggressive antimicrobial treatment and the replacement of warfarin with low-dose aspirin.
Histopathological examination of the bullous lesions revealed an atrophic epidermis with marked keratinocyte necrosis, as well as severe hydropic degeneration of the basal layer with blister formation and papillary dermal edema. Dermis also showed perivascular and periadnexal mononuclear cell infiltrate and erythrocyte extravasation (Figure 4).
These lesions of SLE with blisters healed within 3 weeks with potent topical steroids. For 7 months after the diagnosis of SLE with blisters, the patient's condition was well controlled with progressively decreasing doses of prednisone and hydroxychloroquine, in the absence of cyclophosphamide. Despite taking a low dose of prednisone (0.25 mg/kg/day), the patient developed a pulmonary complication that was believed to be the result of sepsis. The patient later presented with pulmonary hemorrhage and death. Because all cultures were negative and aspirin had been inadvertently withdrawn several weeks before, it is not clear whether the final complication was due to a massive pulmonary thromboembolism or to septic shock.
Blistering eruptions are rare cutaneous manifestations of SLE that can result from two distinct mechanisms, as illustrated by the two patients described here. In the first case, vesicles resulted from a subepidermal blistering disease with an acute neutrophil-predominant infiltrate in the upper dermis, known as bullous SLE [1, 13]. In the second case, blisters developed from hydropic degeneration of the basal layer and severe edema in the upper dermis, also referred to as SLE with blisters [1, 14].
Bullous SLE is a rare, transient autoimmune bullous disease that occurs in established cases of SLE . It appears in less than 5% of patients with SLE, either in isolation or in addition to other cutaneous manifestations . This condition usually affects young females, with only eleven cases reported in children [3–13] until now.
The association of bullous SLE with lupus nephritis has been reported in adults [15–17]. It appears that the close relationship between bullous SLE and lupus nephritis is also important in children, as demonstrated by Sirka et al , Vijayalakshmi and Jayavardhana , Kumar and Agarwal , and the first of the two cases presented here.
The relationship between lupus nephritis and bullous SLE does not appear to be casual. Onetti Muda et. al  demonstrated that type VII collagen, which is usually not present in normal glomeruli, is actively synthesized and incorporated in areas of glomerular and/or tubular scarring, irrespective of the underlying disease (including SLE nephritis). These findings confirm the de novo expression of fibrillary collagens in the diseased renal extracellular matrix.
Systemic lupus erythematosus is a multisystem heterogeneous autoimmune disease and auto-antibodies directed against several components of the cell have been described. It can be hypothesized that bullous SLE develops in patients with lupus nephritis once type VII collagen deposition has occurred in an abnormal location (e.g., the kidney) and antibody production towards this abnormally located protein has been initiated. Type VII collagen is the major component of anchoring fibrils at the dermal-epidermal junction, and is the target of autoimmunity in patients with bullous SLE . There has been at least one report of bullous eruption as the first clinical sign of SLE relapse  suggesting that skin damage can be a marker of disease activity.
The second patient described in this report developed SLE with blisters, which is also a rare manifestation of SLE both in adults and children. The actual incidence of this condition is difficult to ascertain, especially because some cases are reported under the term 'bullous SLE', even when the patients do not have the typical autoimmune blistering disease with acute neutrophilic upper dermal infiltrate and subepidermal separation, as well as positive direct immunofluorescence tests. However, of the 148 pediatric SLE cases that have been examined in our lupus clinic over the last 8 years, this is our first incidence of SLE with blisters.
As opposed to bullous SLE, SLE with blisters has not been associated with specific systemic lupus manifestations and therefore does not necessarily imply a worse prognosis. This LE-specific lesion represents a severe dermo-epidermal edema, which is not directed towards specific antigens.
The differential diagnosis of blistering eruptions in patients with SLE includes dermatitis herpetiformis and bullous pemphigoid which are clinically similar but can be differentiated by direct immunofluorescence. Bullous lesions in SLE due to photosensitivity, acute lupus or drugs can be differentiated by both histopathology and immunopathology. Epidermolysis bullosa acquisita (EBA) is histopathologically and immunopathologically identical since both are mediated by circulating antibodies against type VII collagen. However, a dramatic therapeutic response to dapsone in bullous SLE differentiates it from EBA . When in a linear disposition, herpes zoster can be considered in the differential, but it can be easily differentiated by histopathology .
It seems contradictory that the patient with bullous SLE continued to thrive, whereas the patient with SLE with blisters, which are apparently not associated with any further risk, had a fatal clinical course. However, the cause of death in the latter case could be related to an APS relapse when the patient developed what has been called "catastrophic APS" after low-dose aspirin was inadvertently withdrawn. There were no other signs or symptoms of SLE disease activity, cyclophosphamide had been stopped, and the prednisone dose was low. Therefore, the patient had a low risk of developing a septic event due to the immunosuppressive effects of medical treatment.
The recognition and correct diagnosis of two different mechanisms of blistering production in SLE is mandatory, as bullous SLE implies the risk of lupus nephritis and can sometimes be the first manifestation of the disease [16, 21], whereas SLE with blisters does not generally imply further risk of disease activity or a bad prognosis.
Clinical photographs were taken with oral consent from the parents in both cases. The identity of the patients cannot be disclosed from the reports and the clinical photographs do not reveal any recognizable feature of either. Besides, the Ethical Committee at our Hospital has found no objection to the publication of both cases.
Yell JA, Wojnarowska F: Bullous skin disease in lupus erythematosus. Lupus. 1997, 6: 112-21. 10.1177/096120339700600206.
Vassileva S: Bullous systemic lupus erythematosus. Clin Dermatol. 2004, 22: 129-38. 10.1016/j.clindermatol.2003.12.020.
Jacoby RA, Abraham AA: Bullous dermatosis and systemic lupus erythematosus in a 15-year-old-boy. Arch Dermatol. 1979, 115: 1094-97. 10.1001/archderm.115.9.1094.
Hall RP, Lawley TJ, Smith HR, Katz SI: Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med. 1982, 197: 165-70.
Kettler AH, Bean SF, Duffy JO, Gammon WR: Systemic lupus erythematosus presenting as a bullous eruption in a child. Arch Dermatol. 1988, 124: 1083-87. 10.1001/archderm.124.7.1083.
Roholt NS, Lapiere JC, Wang JI, Bernstein LJ, Woodley DT, Eramo LR: Localized linear bullous eruption of systemic lupus erythematosus in a child. Pediatr Dermatol. 1995, 12: 138-44. 10.1111/j.1525-1470.1995.tb00140.x.
Shirhama S, Furukawa F, Yagi H, Tanaka T, Hashimoto T, Takigawa M: Bullous systemic lupus erythematosus: detection of antibodies against noncollagenous domain of type VII collagen. J Am Acad Dermatol. 1998, 38: 844-48. 10.1016/S0190-9622(98)70472-4.
Chan LS, Lapier JC, Chen M, Traczyk T, Mancini AJ, Paller AS, Woodley DT, Marinkovich MP: Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol. 1999, 135: 569-73. 10.1001/archderm.135.5.569.
Nitta Y, Kawamwa C, Hashimoto T: Vesicullobullous systemic lupus erythematosus: a case with circulating IgG and IgA autoantibodies to type VII collagen. J Am Acad Dermatol. 2002, 47 (5 suppl): 283-86. 10.1067/mjd.2002.109251.
Harris-Stith R, Ericsson QL, Elston DM, David-Bajar K: Bullous eruption: a manifestation of lupus erythematosus. Cutis. 2003, 72: 31-37.
Sirka CS, Padhi T, Mohanty P, Patel DK, Parida PR, Kar CR: Bullous systemic lupus erythematosus: response to dapsone in two patients. Indian J Dermatol Venereol Leprol. 2005, 71: 54-56. 10.4103/0378-6323.13795.
Vijayalakshmi AM, Jayavardhana A: Bullous systemic lupus erythematosus and lupus nephritis in a 10-year-old boy. Indian Pediatrics. 2007, 44: 861-63.
Kumar S, Agarwal I: Unusual presentation of childhood systemic lupus erythematosus. Pediatr Rheumatol Online J. 2007, 31 (5): 20-10.1186/1546-0096-5-20.
Burrows NP, Bhogal BS, Black MM, Rustin MH, Ishida-Yamamoto A, Kirtschig G, Russel Jones R: Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases. Br J Dermatol. 1993, 128: 332-38. 10.1111/j.1365-2133.1993.tb00180.x.
Dhir R, Desylva PLK, Gehi N, Malik A, Singh YD, Jagannayakulu H, Tampi PS, Ramasethu R: Pericardial effusion with vesiculobullous lesions in a young female. Bullous systemic lupus erythematosus (bullous SLE). Indian J Dermatol Venereol Leprol. 2006, 72: 175-77. 10.4103/0378-6323.25657.
Fujimoto W, Hamada T, Yarmada J, Matsuura H, Iwatsuki K: Bullous systemic lupus erythematosus as an initial manifestation of SLE. J Dermatol. 2005, 32: 1021-27.
Ng YY, Chang IT, Chen TW, Liou HN, Yang AH, Yang WC: Concomitant lupus nephritis and bullous eruption in systemic lupus erythematosus. Nephrol Dial Transplant. 1999, 14: 1739-43. 10.1093/ndt/14.7.1739.
Onetti Muda A, Ruzzi L, Bernardini S, Teti A, Faraggiana T: Collagen VII expression in glomerula sclerosis. J Pathol. 2001, 195 (3): 383-90. 10.1002/path.962.
Gammon WR, Briggaman RA: Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol. 1993, 100 (1): 28S-34S. 10.1111/1523-1747.ep12355210.
Malcangi G, Brandozzi G, Giangiacomi M, Zampetti M, Danieli MG: Bullous SLE: response to methotrexate and relationship with disease activity. Lupus. 2003, 12 (1): 63-66. 10.1191/0961203303lu241cr.
Fujimoto W, Hamada T, Yamada J, Matsuura H, Iwatsuki K: Bullous systemic lupus erythematosus as an initial manifestation of SLE. J Dermatol. 2005, 32 (12): 1021-27.
The authors declare that they have no competing interests.
MSO and FER contributed in taking care of the patients, preparing the manuscript and reviewing the final draft. ELC and BLB contributed in reading the skin biopsies, preparing the manuscript and reviewing the final draft.